journal article·2026-02Open access

Smart Nanoparticles Disrupting Energy Supply through Triple Mechanisms to Kill Tumors via Dual Disruption of Mitochondria and Lysosomes

Xiao Xu, Qiqing Huang, Yang Liu, Jinzhuo Liu, Deyi Yang, Yanni Song, Xin Han

Advanced Science· Volume 13· Issue 7

Abstract

Abstract Targeting mitochondrial disruption as a strategy for inhibiting cancer cell proliferation presents a promising therapeutic approach. However, the process of mitophagy plays a protective role in cancer cells by aiding in damage repair, regulating energy metabolism, and promoting the development of drug resistance. Therefore, designing precise therapies that selectively damage mitochondria while inhibiting mitophagy remains a challenge. This study develops a biomimetic nanoplatform (MTCA@C) with hollow MnO 2 as the core, loaded with tetrandrine and mitochondrial‐targeted photosensitizer (Ce6‐Apt), and coated with a cell membrane. Under the targeting of the ligand and irradiation of external near‐infrared light, Ce6‐Apt reaches the mitochondria to induce photodynamic reactions causing mitochondrial dysfunction, while also activating mitophagy. Tetrandrine induces lysosomal alkalinization, effectively disrupting the mitophagic flow, and Tet also causes macropinocytosis, characterized by excessive intracellular vacuole accumulation and expansion, leading to cell rupture and ultimately inducing methuosis. Notably, the synergistic effect of these three mechanisms cuts off the energy supply of tumor cells, achieving spatiotemporally controlled precision therapy. In summary, a biomimetic nanoplatform is designed that precisely disrupts the interaction between mitochondria and lysosomes to impair the compensatory energy supply of tumors, addressing the challenge of drug resistance in cancer treatment.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Advanced Nanomaterials in Catalysis · Autophagy in Disease and Therapy

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Jiangsu Key Laboratory for Pharmacology and Safety Research of Chinese Materia Medica School of Medicine Nanjing University of Chinese Medicine Nanjing 210023 China

Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Shenzhen 518116 China

Department of Breast Surgery Harbin Medical University Cancer Hospital 150 Haping Road Harbin 150081 China

Funding

National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province

References (36)

Show source-provided references
1. 10.1016/j.cell.2024.04.03710.1016/j.cell.2024.04.037 ↗
2. 10.1038/s41580‐023‐00676‐x10.1038/s41580‐023‐00676‐x ↗
3. 10.1038/s41586‐024‐07835‐w10.1038/s41586‐024‐07835‐w ↗
4. 10.1038/s41467‐023‐39811‐910.1038/s41467‐023‐39811‐9 ↗
5. 10.1093/hmg/ddaa24310.1093/hmg/ddaa243 ↗
6. 10.1073/pnas.200323611710.1073/pnas.2003236117 ↗
7. 10.1038/nature2548610.1038/nature25486 ↗
8. 10.1083/jcb.20220614010.1083/jcb.202206140 ↗
9. 10.7150/thno.7987610.7150/thno.79876 ↗
10. 10.1038/s42255‐023‐00930‐810.1038/s42255‐023‐00930‐8 ↗
11. 10.1016/j.tibs.2020.07.00610.1016/j.tibs.2020.07.006 ↗
12. 10.1146/annurev‐biochem‐030222‐10250510.1146/annurev‐biochem‐030222‐102505 ↗
13. 10.1080/15548627.2021.200875210.1080/15548627.2021.2008752 ↗
14. 10.1038/nrc.2017.5310.1038/nrc.2017.53 ↗
15. 10.1016/j.scib.2024.02.00810.1016/j.scib.2024.02.008 ↗
16. 10.1016/j.scib.2021.11.00310.1016/j.scib.2021.11.003 ↗
17. 10.1038/s41467‐022‐32689‐z10.1038/s41467‐022‐32689‐z ↗
18. 10.1016/j.ymthe.2021.06.01010.1016/j.ymthe.2021.06.010 ↗
19. 10.1126/sciadv.adi196510.1126/sciadv.adi1965 ↗
20. 10.1002/advs.20170058510.1002/advs.201700585 ↗
21. 10.1021/acsnano.4c0846810.1021/acsnano.4c08468 ↗
22. 10.1002/advs.20190284710.1002/advs.201902847 ↗
23. 10.1080/15548627.2018.147431410.1080/15548627.2018.1474314 ↗
24. 10.1038/s41467‐022‐32689‐z10.1038/s41467‐022‐32689‐z ↗
25. 10.3390/cancers302227410.3390/cancers3022274 ↗
26. 10.1016/j.phrs.2024.10731410.1016/j.phrs.2024.107314 ↗
27. 10.1038/cddis.2014.8410.1038/cddis.2014.84 ↗
28. 10.1016/j.virs.2024.09.00110.1016/j.virs.2024.09.001 ↗
29. 10.1016/j.cell.2017.04.03110.1016/j.cell.2017.04.031 ↗
30. 10.1016/j.ccell.2021.02.01610.1016/j.ccell.2021.02.016 ↗
31. 10.1016/j.canlet.2022.21604910.1016/j.canlet.2022.216049 ↗
32. 10.1002/advs.20240469310.1002/advs.202404693 ↗
33. 10.1038/s41568‐023‐00574‐610.1038/s41568‐023‐00574‐6 ↗
34. 10.1016/j.scib.2021.07.00310.1016/j.scib.2021.07.003 ↗
35. 10.1073/pnas.191793811710.1073/pnas.1917938117 ↗
36. 10.1002/smll.20220394210.1002/smll.202203942 ↗